Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?

Bonadioa, Renata Colombo; Velho, Pedro Isaacsson; Marta, Guilherme Nader; Nardo, Mirella; Souza, Manoel Carlos L. A.; Muniz, David Qb; Bispo, Raisa Ka; Faraj, Sheila F.; Bastos, Diogo Assed; Dzik, Carlos

doi:10.3332/ecancer.2019.973

Cited by 1 publication

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[58][59][60]63 However, interestingly, in a retrospective cohort study of patients with metastatic nccRCC treated with pazopanib or sunitinib, pazopanib was associated with inferior OS. 64 Thus, while TKI monotherapy has shown some clinical efficacy in nccRCC subtypes, there is much room for improvement.…”

Section: Pazopanibmentioning

confidence: 99%

“…The trials found pazopanib to be well tolerated overall; however, CTCAE grade 3 adverse events were reported in 20% to 55% of patients, the most common being fatigue, diarrhea and hypertension 58‐60,63 . However, interestingly, in a retrospective cohort study of patients with metastatic nccRCC treated with pazopanib or sunitinib, pazopanib was associated with inferior OS 64 . Thus, while TKI monotherapy has shown some clinical efficacy in nccRCC subtypes, there is much room for improvement.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options

Wilson,

Acikgoz,

Hasanov

2023

Intl Journal of Cancer

View full text Add to dashboard Cite

Non‐clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. Compared to clear‐cell RCC (ccRCC), nccRCC typically has a worse prognosis in the metastatic setting, with overall survival durations that are ~10 months shorter. The nccRCC consists of a wide range of different histological subtypes, the majority of which are composed of papillary, chromophobe, renal medullary carcinoma, translocation RCC, collecting duct carcinoma and unclassified RCC. Most clinical trials have either excluded or only included small numbers of patients with nccRCC; owing to the lack of prospective studies focusing on this population, data on response rates and survival outcomes are lacking. NccRCC treatment is a nascent field with various therapeutic modalities and combinations under investigation, often based on data extrapolated from therapeutic studies in ccRCC. We herein review the use and outcomes of cytotoxic chemotherapy, various combination modalities of tyrosine kinase inhibitors and immune checkpoint inhibitors, and targeted agents. We discuss active ongoing clinical trials for patients with nccRCC and future directions in the treatment of this rare disease. Historically, treatment for nccRCC has been adopted from the standard of care for patients with ccRCC, although these treatments are less effective in the nccRCC population. As we begin to understand the underlying biology of these tumors, clinical trials have been able to slowly accrue and include more patients with various subtypes of nccRCC. There remains much room for improvement in this area of need, but there is hope on the horizon.

show abstract